Research Studies and Clinical Trials Search
Results
Chronic Kidney Disease (CKD) and Iron Deficiency Anemia: A study on ferumoxytol treatment for CKD and iron deficiency
Iron deficiency anemia (IDA) is common in adults and children who have chronic kidney disease (CKD). Iron therapy is the usual treatment for IDA. Iron therapy has been shown to restore iron levels and help the body normalize levels of hemoglobin (the part of your blood that...
Iron deficiency anemia (IDA) is common in adults and children who have chronic kidney disease (CKD). Iron therapy is the usual treatment for IDA. Iron therapy has been shown to restore iron levels and help the body normalize levels of hemoglobin (the part of your blood that carries oxygen). The purpose of this research study is to evaluate the experimental drug ferumoxytol when compared to iron sucrose in children with CKD and iron deficiency anemia or who are at risk of developing IDA. Another purpose of the study is to see what happens to ferumoxytol in children's bodies and how the body clears the drug from blood. This is called pharmacokinetics (PK). PK blood samples will be obtained from some ferumoxytol-treated subjects who agree to have these samples taken. The study doctor may ask subjects to participate in this part of the study or inform them that PK samples are not needed.
Chronic Kidney Disease (CKD): A study on ferric citrate to maintain or improve iron and phosphate levels
The purpose of this placebo-controlled study is to determine how well ferric citrate will lower the level of FGF23, maintain or correct anemia and iron levels in the blood and maintain normal levels of serum phosphate in children with CKD stages 3 and 4 that is, between 15% and...
The purpose of this placebo-controlled study is to determine how well ferric citrate will lower the level of FGF23, maintain or correct anemia and iron levels in the blood and maintain normal levels of serum phosphate in children with CKD stages 3 and 4 that is, between 15% and 60% of normal function. Ferric citrate is an oral medication that is approved by the U.S. Food and Drug Administration (FDA) for use in adults with kidney disease to control serum phosphate levels, but it has not been approved for use in children. The use of ferric citrate is considered investigational, which means it has not been approved for the way it is being used in this study.
Hemodialysis Registry: A tool used to collect health information on children receiving hemodialysis for future research
The purpose of this research study is to continuously monitor outcomes in children around the world that are on hemodialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators, and...
The purpose of this research study is to continuously monitor outcomes in children around the world that are on hemodialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators, and help improve the wellbeing of children currently on HD. Being in this study involves having data collected from the child's medical record by a study team member and entered into an international database (registry). The data to be entered will include the child's date of birth, a unique study number, dates of service, and relevant medical information.
Kidney Disease (FSGS, Alport syndrome, IgA nephropathy): A clinical trial of sparsentan treatment for kidney diseases
Travere Therapeutics, Inc. (the Sponsor) is running a research study to see if a study drug, not yet approved for use by the United States Food and Drug Administration (FDA), named sparsentan, will help in the treatment of kidney diseases and if it is safe to use in people.
Travere Therapeutics, Inc. (the Sponsor) is running a research study to see if a study drug, not yet approved for use by the United States Food and Drug Administration (FDA), named sparsentan, will help in the treatment of kidney diseases and if it is safe to use in people.
Kidney Failure Registry: A tool used to collect health information on children less than 21 years old with kidney failure for future research
The purpose of this research study is to gather data on all children less than 21 years of age with kidney failure who receive treatment in the United States, Canada, and Mexico in order to evaluate patient characteristics and outcomes of treatment used in pediatric patients in...
The purpose of this research study is to gather data on all children less than 21 years of age with kidney failure who receive treatment in the United States, Canada, and Mexico in order to evaluate patient characteristics and outcomes of treatment used in pediatric patients in North America. Being in this study involves the collection of data from the person's medical record by a qualified member of the nephrology team. Children who are entered into this study will not have procedures or treatments which are different from those routinely performed as part of their ongoing medical care. The child's date of birth, a unique study number, dates of service, and relevant medical information will be collected on special computerized forms. These forms will be transmitted by computer to EMMES (a data collection company used by NAPRTCS). The data transmission process is secured for patient confidentiality.
Nephrotic Syndrome Registry: A tool used to collect health information and laboratory samples to learn more about kidney diseases
Childhood onset nephrotic syndrome is a condition which affects the kidneys, causing them to leak protein from the blood into the urine. Nephrotic syndrome is a disease that can improve (remission) and worsen (relapse) at different times throughout childhood. NEPTUNE is a large...
Childhood onset nephrotic syndrome is a condition which affects the kidneys, causing them to leak protein from the blood into the urine. Nephrotic syndrome is a disease that can improve (remission) and worsen (relapse) at different times throughout childhood. NEPTUNE is a large North American study consisting of over 500 individuals and more than 5 years of research. By collecting health information and laboratory samples, our goal is to learn more about these kidney diseases and find better ways to prevent and treat people with nephrotic syndrome. New knowledge will be shared with researchers and the public.
Peritoneal Dialysis Registry: A tool used to collect health information on children receivin peritoneal dialysis for future research
The purpose of this research study is to continuously monitor outcomes in children around the world that are on peritoneal dialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators...
The purpose of this research study is to continuously monitor outcomes in children around the world that are on peritoneal dialysis. This registry should provide much needed information to doctors, nurses, dieticians, psychologists, social workers, and health care administrators, and help improve the wellbeing of children currently on PD. Being in this study involves having data collected from the child's medical record by a study team member and entered into an international database (registry). The data to be entered will include the child's date of birth, a unique study number, dates of service, and relevant medical information.
Polycystic Kidney Disease (PKD): Blood, urine, and information collected and stored for research on better understanding PKD
This study is for ages 4-18. EPOC is an observational cohort of young patients with early ADPKD. A repository or biological samples and kidney imaging from these patients will be made available to the PKD research community to discover new prognostic biomarkers. Children...
This study is for ages 4-18. EPOC is an observational cohort of young patients with early ADPKD. A repository or biological samples and kidney imaging from these patients will be made available to the PKD research community to discover new prognostic biomarkers. Children diagnosed with PKD and undiagnosed siblings of PKD participants may be enrolled